Geoff Meacham
Stock Analyst at B of A Securities
(4.26)
# 352
Out of 5,169 analysts
291
Total ratings
58.06%
Success rate
11.83%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $145 → $130 | $90.00 | +44.44% | 3 | Mar 11, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $97 → $85 | $55.43 | +53.35% | 4 | Mar 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $575 → $585 | $451.59 | +29.54% | 7 | Mar 10, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $55 → $58 | $39.79 | +45.77% | 2 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $110 → $120 | $79.14 | +51.63% | 8 | Mar 2, 2026 | |
| MANE Veradermics | Initiates: Buy | $85 | $59.01 | +44.04% | 1 | Mar 2, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $110 → $115 | $114.51 | +0.43% | 2 | Feb 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $15 → $19 | $13.79 | +37.78% | 6 | Feb 20, 2026 | |
| BIIB Biogen | Maintains: Neutral | $185 → $215 | $182.31 | +17.93% | 19 | Feb 9, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $64 | $59.37 | +7.80% | 9 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $115 → $120 | $114.50 | +4.80% | 11 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $315 → $345 | $351.48 | -1.84% | 14 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $230 | $208.34 | +10.40% | 22 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $156 | $141.29 | +10.41% | 9 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $45.79 | +9.19% | 4 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $13.00 | +284.62% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $115 | $97.09 | +18.45% | 4 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $49 | $13.86 | +253.54% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $26 | $27.32 | -4.83% | 7 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $2.92 | +173.97% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $67.00 | +11.94% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $744.12 | -5.93% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $52.40 | -46.56% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $29.44 | +69.84% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $45.15 | +10.74% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $47.69 | +95.01% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $9.32 | +50.21% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $70.12 | -22.99% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $10.01 | -40.06% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $2.64 | -62.12% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $66.77 | +42.28% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.65 | +142.42% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $918.05 | +19.82% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $20.06 | -0.30% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $38.05 | -18.53% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $237.28 | -28.35% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.19 | +1,328.57% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.66 | +1,345.78% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $10.95 | -63.47% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $13.50 | +107.41% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.30 | +1,378.26% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $2.51 | +1,297.21% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.50 | +2,709.36% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $7.43 | +169.18% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.36 | +5,455.56% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $6.00 | +50.00% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $8.28 | +624.64% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $23.45 | -1.92% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $92.24 | -11.10% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $530.35 | -82.09% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $19.45 | +311.31% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $130.71 | +3.28% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.59 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.17 | +530.91% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $9.09 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $314.80 | -49.81% | 5 | Nov 8, 2017 |
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $145 → $130
Current: $90.00
Upside: +44.44%
BioMarin Pharmaceutical
Mar 11, 2026
Maintains: Buy
Price Target: $97 → $85
Current: $55.43
Upside: +53.35%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $575 → $585
Current: $451.59
Upside: +29.54%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $55 → $58
Current: $39.79
Upside: +45.77%
Kymera Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $110 → $120
Current: $79.14
Upside: +51.63%
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $85
Current: $59.01
Upside: +44.04%
Arcellx
Feb 24, 2026
Downgrades: Neutral
Price Target: $110 → $115
Current: $114.51
Upside: +0.43%
Amylyx Pharmaceuticals
Feb 20, 2026
Maintains: Buy
Price Target: $15 → $19
Current: $13.79
Upside: +37.78%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $185 → $215
Current: $182.31
Upside: +17.93%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Neutral
Price Target: $60 → $64
Current: $59.37
Upside: +7.80%
Feb 4, 2026
Maintains: Neutral
Price Target: $115 → $120
Current: $114.50
Upside: +4.80%
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $345
Current: $351.48
Upside: -1.84%
Jan 27, 2026
Maintains: Neutral
Price Target: $235 → $230
Current: $208.34
Upside: +10.40%
Jan 27, 2026
Maintains: Buy
Price Target: $140 → $156
Current: $141.29
Upside: +10.41%
Jan 27, 2026
Maintains: Buy
Price Target: $48 → $50
Current: $45.79
Upside: +9.19%
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $13.00
Upside: +284.62%
Dec 8, 2025
Maintains: Buy
Price Target: $98 → $115
Current: $97.09
Upside: +18.45%
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $13.86
Upside: +253.54%
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $27.32
Upside: -4.83%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.92
Upside: +173.97%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $67.00
Upside: +11.94%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $744.12
Upside: -5.93%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $52.40
Upside: -46.56%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $29.44
Upside: +69.84%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $45.15
Upside: +10.74%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $47.69
Upside: +95.01%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $9.32
Upside: +50.21%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $70.12
Upside: -22.99%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $10.01
Upside: -40.06%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $2.64
Upside: -62.12%
Mar 13, 2025
Initiates: Buy
Price Target: $95
Current: $66.77
Upside: +42.28%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.65
Upside: +142.42%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $918.05
Upside: +19.82%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $20.06
Upside: -0.30%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $38.05
Upside: -18.53%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $237.28
Upside: -28.35%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.19
Upside: +1,328.57%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.66
Upside: +1,345.78%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $10.95
Upside: -63.47%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $13.50
Upside: +107.41%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.30
Upside: +1,378.26%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $2.51
Upside: +1,297.21%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.50
Upside: +2,709.36%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $7.43
Upside: +169.18%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.36
Upside: +5,455.56%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $6.00
Upside: +50.00%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $8.28
Upside: +624.64%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $23.45
Upside: -1.92%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $92.24
Upside: -11.10%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $530.35
Upside: -82.09%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $19.45
Upside: +311.31%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $130.71
Upside: +3.28%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $8.59
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.17
Upside: +530.91%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.09
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $314.80
Upside: -49.81%